-
2024-519745-30-00
9
Immune Thrombocytopenia (ITP)
-
2025-520581-22-00
4
Allergic rhinoconjunctivitis caused due to exposure to pollen grasses
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-518026-32-00
5
Invasive Breast Cancer
-
2024-519709-37-00
5
Paroxysmal nocturnal hemoglobinuria (PNH)
-
2024-520336-14-00
5
Post-chemotherapy neutropenia with high risk of developing infection i
-
2025-522791-92-00
5
Neoplasm Metastasis
-
2025-523238-17-00
4
Acute myeloid leukemia
-
2025-523396-38-00
9
Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r high
-
2025-524810-28-00
5
Acute Promyelocytic Leukemia
-
2024-511496-14-00
5
2026-05-14
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2024-512436-29-00
11
2026-03-27
CARDIOVASCULAR DISEASES
-
2025-521919-39-00
3
2026-02-10
Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment
-
2024-518936-36-00
6
2026-01-23
Active smokers
-
2024-512360-55-00
4
2025-06-30
Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
-
2023-507936-20-00
5
2025-05-05
Acute myeloid leukemia
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2024-513219-29-00
5
2024-10-21
Renal Cell Carcinoma
-
2023-510017-26-00
1
2024-10-02
Completely Resected Stage IIB, IIC, and III Melanoma
-
2022-501709-11-00
5
2023-06-06
Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms